Starbucks Corp (NASDAQ:SBUX, ETR:SRB) stock frothed up afterhours as the coffee giant reported better-than-expected results for the fiscal first quarter, the first full quarter under the leadership of new CEO Brian Niccol.
For the period which ended December 29, 2024, Starbucks reported earnings per share of $0.69, above estimates of $0.66. This represented a 23% decline from the year-ago quarter.
HIVE Digital Technologies (TSX-V:HIVE, NASDAQ:HIVE) announced it has signed a binding letter of intent (LOI) to acquire Bitfarms Ltd's Yguazú 200-megawatt (MW) hydro-powered Bitcoin mining facility in Paraguay for $56 million.
The acquisition is expected to increase HIVE's global Bitcoin mining capacity from 6 Exahash per second (EH/s) to 25 EH/s by September 2025, according to a statement from the company.
JetBlue Airways Corp (NASDAQ:JBLU) shares dove over 25% to $6 after the company reported better than expected earnings but cautioned that capacity would be down in the first quarter of 2025.
JetBlue said available seat miles (ASM) in the first quarter are likely to fall 2-5% compared to a year earlier, and are on course to be roughly flat for the whole year.
Royal Caribbean Cruises Ltd (NYSE:RCL) shares surged almost 10% after the cruise operator reported strong fourth quarter earnings attributed to strong pricing and onboard revenue streams.
For the quarter, adjusted earnings per share (EPS) grew to $1.63 from $1.25 in the year-ago quarter, above the Wall Street consensus of $1.50.
General Motors Company (NYSE:GM) shares fell 8.4% to $50.30 in early trading on Tuesday even though the Chevrolet, Cadillac, GMC and Buick maker reported better than expected earnings and its EV business was "variable profit positive" for the first time.
The auto manufacturer reported a fourth-quarter net loss of $3 billion and adjusted earnings of $2.5 billion, with net income reduced by more than $5 billion, mainly from restructuring and impairment changes relating to its China joint ventures that was confirmed in December.
Lockheed Martin Corp (NYSE:LMT) shares misfired on Tuesday, falling 4% pre-market to $483.3, after the defence giant's fourth-quarter earnings and guidance for 2025 were lower than analysts had expected.
Quarterly net sales came in at $18.6 billion, down 1.6% year-on-year and short of the average Wall Street forecast of $18.84 billion.
Shares in Nuformix PLC surged 44% in early trading after the company announced it had submitted an application to the European Medicines Agency (EMA) for Orphan Drug Designation for its lead asset, NXP002.
The treatment is an inhaled therapy targeting Idiopathic Pulmonary Fibrosis (IPF), a rare and life-threatening lung condition.